These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21553090)

  • 21. Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease.
    Kumakura Y; Danielsen EH; Reilhac A; Gjedde A; Cumming P
    Acta Neurol Scand; 2004 Sep; 110(3):188-95. PubMed ID: 15285777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification and discriminative power of
    Delva A; Van Weehaeghe D; van Aalst J; Ceccarini J; Koole M; Baete K; Nuyts J; Vandenberghe W; Van Laere K
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1913-1926. PubMed ID: 31776633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
    Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM
    J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olfactory dysfunction correlates with putaminal dopamine turnover in early de novo Parkinson's disease.
    Löhle M; Wolz M; Beuthien-Baumann B; Oehme L; van den Hoff J; Kotzerke J; Reichmann H; Storch A
    J Neural Transm (Vienna); 2020 Jan; 127(1):9-16. PubMed ID: 31863171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
    Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
    Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
    Morrish PK; Rakshi JS; Bailey DL; Sawle GV; Brooks DJ
    J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):314-9. PubMed ID: 9527140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study.
    Whone AL; Bailey DL; Remy P; Pavese N; Brooks DJ
    J Nucl Med; 2004 Jul; 45(7):1135-45. PubMed ID: 15235059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
    Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
    Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
    Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
    Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes.
    la Fougère C; Pöpperl G; Levin J; Wängler B; Böning G; Uebleis C; Cumming P; Bartenstein P; Bötzel K; Tatsch K
    J Nucl Med; 2010 Apr; 51(4):581-7. PubMed ID: 20237026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Striatal dopa and glucose metabolism in PD patients with freezing of gait.
    Bartels AL; de Jong BM; Giladi N; Schaafsma JD; Maguire RP; Veenma L; Pruim J; Balash Y; Youdim MB; Leenders KL
    Mov Disord; 2006 Sep; 21(9):1326-32. PubMed ID: 16721756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders.
    Stormezand GN; Chaves LT; Vállez García D; Doorduin J; De Jong BM; Leenders KL; Kremer BPH; Dierckx RAJO
    Neuroimage Clin; 2020; 25():102161. PubMed ID: 31981888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms.
    Sossi V; de la Fuente-Fernández R; Holden JE; Schulzer M; Ruth TJ; Stoessl J
    J Cereb Blood Flow Metab; 2004 Aug; 24(8):869-76. PubMed ID: 15362717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative assessment of 6-[
    Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
    J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
    Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
    Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
    Nurmi E; Ruottinen HM; Bergman J; Haaparanta M; Solin O; Sonninen P; Rinne JO
    Mov Disord; 2001 Jul; 16(4):608-15. PubMed ID: 11481683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
    Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS
    Brain; 1990 Oct; 113 ( Pt 5)():1539-52. PubMed ID: 2123119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using 123I-iodolisuride SPET.
    Baulieu JL; Ribeiro MJ; Levilion-Prunier C; Tranquart F; Chartier JR; Guilloteau D; Cottier JP; Besnard JC; Pourcelot L; Autret A
    Nucl Med Commun; 1999 Jan; 20(1):77-84. PubMed ID: 9949416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients.
    Huang WS; Chiang YH; Lin JC; Chou YH; Cheng CY; Liu RS
    J Nucl Med; 2003 Jul; 44(7):999-1005. PubMed ID: 12843212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.